Sientra (SIEN) Given “Buy” Rating at Maxim Group
Maxim Group restated their buy rating on shares of Sientra (NASDAQ:SIEN) in a research report report published on Monday. The brokerage currently has a $20.00 price target on the medical instruments supplier’s stock.
Other analysts have also recently issued reports about the stock. ValuEngine cut shares of Sientra from a strong-buy rating to a buy rating in a report on Thursday, January 24th. Zacks Investment Research raised shares of Sientra from a sell rating to a hold rating in a report on Wednesday, November 7th. Finally, BidaskClub cut shares of Sientra from a hold rating to a sell rating in a report on Tuesday, November 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of Buy and an average price target of $22.63.
Shares of NASDAQ:SIEN opened at $10.43 on Monday. The firm has a market cap of $293.14 million, a price-to-earnings ratio of -3.70 and a beta of -0.03. Sientra has a 1-year low of $8.79 and a 1-year high of $26.79. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.34 and a current ratio of 2.77.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Featured Article: How prevalent are 12b-1 fees?
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.